

1 Detection of SARS-CoV-2 variant Mu, Beta, Gamma, Lambda, Delta, Alpha, and Omicron in  
2 wastewater settled solids using mutation-specific assays is associated with regional detection of  
3 variants in clinical samples

4

5 Marlene Wolfe<sup>a\*</sup>, Bridgette Hughes<sup>b\*</sup>, Dorothea Duong<sup>b</sup>, Vikram Chan-Herur<sup>b</sup>, Krista R.  
6 Wigginton<sup>c</sup>, Bradley J. White<sup>c</sup>, Alexandria B. Boehm<sup>d#</sup>

7

8 a. Gangarosa Department of Environmental Health, Rollins School of Public Health, Emory  
9 University, Atlanta, GA, USA

10 b. Verily Life Sciences, South San Francisco, CA, USA

11 c. Civil & Environmental Engineering, University of Michigan, Ann Arbor, MI, USA

12 d. Civil & Environmental Engineering, Stanford University, Stanford, CA, USA

13

14 \*co-first authors' order chosen as reverse alphabetical order

15 #Address correspondence to: Alexandria Boehm, [aboehm@stanford.edu](mailto:aboehm@stanford.edu)

16

17 Target Journal: Applied and Environmental Microbiology

18

19 Running title (54 characters): SARS-CoV-2 variant RNA in wastewater solids

20

21 **Abstract** (250 words)

22

23 Changes in the circulation of SARS-CoV-2 variants of concern (VOCs) may require changes in  
24 public health response to the COVID-19 pandemic, as they have the potential to evade vaccines  
25 and pharmaceutical interventions and may be more transmissible relative to other SARS-CoV-2  
26 variants. As such, it is essential to track and prevent their spread in susceptible communities.

27 We developed digital RT-PCR assays for mutations characteristic of VOCs and used them to  
28 quantify those mutations in wastewater settled solids samples collected from a publicly owned  
29 treatment works (POTW) during different phases of the COVID-19 pandemic. Wastewater  
30 concentrations of single mutations characteristic to each VOC, normalized by the concentration  
31 of a conserved SARS-CoV-2 N gene, correlate to regional estimates of the proportion of clinical  
32 infections caused by each VOC. These results suggest targeted RT-PCR assays can be used to  
33 detect variants circulating in communities and inform public health response to the pandemic.

34

35 **Importance** (150 words)

36

37 Wastewater represents a pooled biological sample of the contributing community and thus a  
38 resource of assessing community health. Here we show that emergence, spread, and  
39 disappearance of SARS-CoV-2 infections caused by variants of concern are reflected in the  
40 presence of variant genomic RNA in wastewater settled solids. This work highlights an  
41 important public health use case for wastewater.

42

43 Keywords: SARS-CoV-2, Omicron, Wastewater, COVID-19, Delta, Epidemiology

44

45

46 **Introduction**

47

48 During an infectious disease outbreak it is critical to detect cases quickly and estimate the  
49 extent and timing of the outbreak to target interventions to mitigate spread. The detection of  
50 targets associated with infectious agents in wastewater can be used to infer information on the  
51 health of an entire population and provide critical outbreak monitoring services. This technique  
52 has been used widely during the COVID-19 pandemic, as SARS-CoV-2 RNA is readily detectable  
53 in wastewater and concentrations of RNA correlate to laboratory-confirmed COVID-19  
54 infections in the contributing communities (1–4). Wastewater has previously been used to track  
55 gastrointestinal infections including poliovirus (5), and this work has extended to not only track  
56 COVID-19 (6) but also for other respiratory viruses such as respiratory syncytial virus (RSV) (7).  
57 Using wastewater to track community health has the advantage of providing information on an  
58 entire community without relying on individual clinical testing, which may be expensive or  
59 unavailable and requires individuals to alter their behavior to seek testing. Wastewater may be  
60 a leading indicator of community health when shedding by infectious individuals precedes  
61 symptom onset.

62

63 The COVID-19 pandemic has seen SARS-CoV-2 acquire mutations that have given rise to  
64 variants with distinguishing characteristics. Variants of concern (VOCs) or interest (VOIs) are  
65 variants that may evade vaccines or other pharmaceutical interventions, be more transmissible,

66 or cause more severe illness. Variant classifications by the World Health Organization (WHO)  
67 and the US Centers for Disease Control and Prevention (CDC) have changed over the course of  
68 the pandemic, but VOCs are named according to the Greek alphabet and have included Alpha,  
69 Beta, Gamma, Delta, Lambda, Mu, and Omicron (8, 9). The emergence of variants is primarily  
70 identified by sequencing of clinical specimens; this same approach is then typically used to track  
71 the spread of VOCs into and throughout communities. A health department or clinical  
72 laboratory will choose a subset of all specimens to sequence, and results are usually available  
73 within two weeks. This data could lack community representation if samples from some clinics  
74 are more likely to be sequenced than others, or may be biased when specific samples are  
75 chosen for sequencing because of patient characteristics. A two week processing time may  
76 prevent a fast public health response to a spreading variant of concern.

77  
78 Monitoring variants in wastewater may overcome some of the problems with relying on  
79 sequencing clinical specimens to track variant emergence and spread. A wastewater sample is  
80 representative of the entire contributing community and therefore lacks bias that is common  
81 for sequencing of clinical specimens. However, a wastewater sample is more complex than a  
82 clinical specimen: it contains many different types of viruses (10) that have undergone different  
83 degrees of degradation (11). Sequencing SARS-CoV-2 RNA from wastewater likely requires  
84 enrichment or amplification of the SARS-CoV-2 genome (12). An alternative approach for  
85 variant tracking in wastewater is application of targeted RT-PCR assays that amplify and allow  
86 detection of short genomic sequences characteristic to the variant.

87

88 Several publications to date have explored the use of targeted assays to detect SARS-CoV-2  
89 variants in wastewater. Heijan et al. (13) applied a commercial digital RT-PCR assay to  
90 wastewater influent samples to detect a single nucleotide polymorphism (SNP) (mutation  
91 N501Y) present Beta and Alpha. Lee et al. (14) and Graber et al. (15) applied RT-QPCR assays  
92 that detect mutations present in Alpha to wastewater samples. Yaniv et al. developed RT-QPCR  
93 assays for Gamma and Delta (16), and Alpha and Beta (17) and applied them to four or 10  
94 wastewater samples, respectively, as proof of concept. To date, there is limited research (18,  
95 19) to apply targeted assays for characteristic mutations of diverse variants to wastewater  
96 samples across different phases of the pandemic to identify emergence patterns, and compare  
97 those to data from variants in clinical specimens.

98  
99 The present study develops novel targeted digital droplet (dd-)RT-PCR assays for the detection  
100 of six characteristic mutations from distinct variants in wastewater. In particular, we develop  
101 and utilize assays for mutations characteristic of Alpha, Beta & Gamma, Delta, Mu, Lambda, and  
102 Omicron and then measure these in wastewater solids from a publicly owned treatment work  
103 (POTW) located in the Bay Area of California, USA. We measure concentrations in wastewater  
104 settled solids as concentrations of SARS-CoV-2 RNA are enriched several orders of magnitude in  
105 solids relative to liquid wastewater (20, 21). We subsequently compare the measurements to  
106 data on occurrence of those variants in clinical specimens, aggregated at the state-level.

107

## 108 **Materials and methods**

109

110 **Assay Development.** Assays were designed to target mutations characteristic of the following  
111 variants: Alpha (HV69-70), Delta (del156-157/R158G), Beta & Gamma (together)  
112 (E484K/N501Y), Mu (del256-257), Lambda (del247-253), and Omicron (del143-145) (Table 1).  
113 These characteristic mutations were chosen because they are present in high percentages of  
114 the associated variant sequences in GISAID (Table 1, information accessed through  
115 outbreak.info), and they represent deletions or multiple single nucleotide polymorphisms  
116 (SNPs) in close proximity and thus are likely to be more specific than assays targeting a SNP.  
117 Assays were developed in silico using Primer3Plus (<https://primer3plus.com/>). Mutation and  
118 adjacent sequences were obtained from genomes downloaded from NCBI. The parameters  
119 used in assay development (that controlled sequence length, GC content, and melt  
120 temperatures) are provided in Table S1. Primers and probe sequences are provided in Table 2.  
121 The development and testing of the HV69-70 and del156-157/R158G are reported elsewhere  
122 (19), so additional details are not provided on these assays herein.

123  
124 **Specificity Screening Against Other Targets.** Primers and probe sequences were screened for  
125 specificity in silico using NCBI Blast, and then tested in vitro against a virus panel (NATtrol™  
126 Respiratory Verification Panel, NATRVP2-BIO, Zeptomatrix) that includes several influenza and  
127 coronavirus viruses, “wild-type” gRNA from SARS-CoV-2 strain 2019-nCoV/USA-WA1/2020  
128 (ATCC® VR-1986D™) which does not contain the mutations (hereafter referred to as WT-gRNA)  
129 as well as a combination of heat inactivated SARS-CoV-2 stain B.1.1.7 (SARS-CoV-2 variant  
130 B.1.1.7, ATCC® VR-3326HK™), a positive clinical sample confirmed as Mu provided by Dr. Ben  
131 Pinsky at Stanford Virology Laboratory, and synthetic gRNA from Twist Biosciences (South San

132 Francisco, California, USA) for Beta (Twist control 16), Gamma (Twist control 17), Delta (Twist  
133 control 23), and Omicron (Twist control 48) (Table 1). RNA was extracted from the virus panel  
134 and whole viruses using the Perkin Elmer Chemagic Viral RNA extraction kit (Chemagic Kit CMG-  
135 1033-S designed for SARS-CoV-2). RNA was used undiluted as template in digital droplet PCR  
136 with mutation primer and probes (see further details on digital PCR below). The concentration  
137 of targets used in the in vitro specificity testing was approximately 275 copies per well. The  
138 mutation assays were challenged against the respiratory panel gRNA in single wells, and non-  
139 target variant gRNA in 8 replicate wells. Positive PCR controls (Table 1) were included on each  
140 plate.

141  
142 The sensitivity and specificity of the mutation assays were further tested by diluting target  
143 variant gRNA (Table 1) for the mutations in no (0 copies), low (100 copies), and high (10,000  
144 copies) background of WT-gRNA. Each dilution was run in three replicate wells. The number of  
145 copies of variant mutation sequences input to each well was estimated using a dilution series of  
146 variant gRNA in no background; the vendor specified concentration of the variant gRNA was  
147 scaled by the slope of the curve relating the measured ddRT-PCR concentration and the  
148 calculated input concentration based on the vendor estimates. Our experience suggests vendor  
149 estimates can be imprecise. PCR negative controls were run in 4 wells per plate.

150  
151 **Wastewater samples.** A publicly owned treatment work (POTW) that serves populations in  
152 Santa Clara County, California, USA (San José-Santa Clara Regional Wastewater Facility) was



153 included in the study. It serves approximately 1,500,000 people; further description of the  
154 POTW can be found in Wolfe et al. (1).

155  
156 Samples of approximately 50 mL of settled solids were collected by POTW staff using sterile  
157 technique in clean, labeled bottles. POTW staff manually collected a 24 h composite sample  
158 (21). Samples were immediately stored at 4°C, transported to the lab, and processed within 6  
159 hours of collection.

160  
161 Samples were collected daily for a larger COVID-19 wastewater surveillance effort starting in  
162 November 2020 (1), and a subset of these samples are used in the present study and were  
163 chosen to span the period prior to and including presumed emergence of different variants.  
164 Generally, sampling was about once per week or month prior to presumed emergence and then  
165 3-7 times per week during and after the period of emergence. Details on sampling frequency  
166 are provided in Table 3. A previous study (19) reported Alpha mutation data for the POTW and  
167 those data are included in our analysis for completeness. That same study reported some Delta  
168 mutation data (N = 48, data until 1 Aug 2021) for the POTW and that data are included here.  
169 The methods below describe those used for the new measurements including those for Mu,  
170 Lambda, Beta/Gamma, Delta (measured daily between 1 Aug 2021 and 2 Jan 2022), and  
171 Omicron mutations.

172  
173 RNA was extracted from the 10 replicate aliquots of dewatered settled solids as described  
174 elsewhere (1, 22, 23). This process includes dilution of the solids in DNA/RNA Shield (Zymo,

175 Irvine, CA) as a means to alleviate inhibition (24). RNA was subsequently processed immediately  
176 (within 24 h of sample collection) to measure concentrations of the N gene of SARS-CoV-2,  
177 pepper mild mottle virus (PMMoV), and bovine coronavirus (BCoV) recovery using digital  
178 droplet RT-PCR methods described in detail elsewhere (1, 25). The N gene assay targets a  
179 region of the N gene that is conserved across these variants. PMMoV is highly abundant in  
180 human stool and wastewater globally (26, 27) and is used as an internal recovery and fecal  
181 strength control for the wastewater samples (28). BCoV was spiked into the samples and used  
182 as an additional recovery control; all samples were required to have greater than 10% BCoV  
183 recovery. RNA extraction and PCR negative and positive controls were included to ensure no  
184 contamination as described in Wolfe et al. (1) The N gene measurement was multiplexed with  
185 the Delta mutation assay in samples processed after Aug 1, 2021, and the Omicron mutation  
186 assay in samples processed after 6 Dec 2021. For the other mutation assays, the extracted RNA  
187 was stored at -80°C for a period of time (Table 3) before it was analyzed for the N gene and the  
188 Mu, Beta/Gamma, or Lambda mutation assay in a multiplex digital RT-PCR assay. The SARS-  
189 CoV-2 N gene was run a second time for assays run on stored RNA to test for RNA degradation  
190 during storage at -80°C (no to minimal degradation was observed, see supporting material, SM).  
191 Each of the 10 replicate RNA extracted were run in its own well, and the 10 wells were merged  
192 for analysis. Wastewater data are available publicly at the Stanford Digital Repository  
193 (<https://purl.stanford.edu/hs561fr5902>); results below are reported as suggested in the EMMI  
194 guidelines for reporting ddRT-PCR measurements in environmental samples (29).

195

196

197 **ddRT-PCR.** Digital RT-PCR was performed on 20  $\mu$ l samples from a 22  $\mu$ l reaction volume,  
198 prepared using 5.5  $\mu$ l template, mixed with 5.5  $\mu$ l of One-Step RT-ddPCR Advanced Kit for  
199 Probes (Bio-Rad 1863021), 2.2  $\mu$ l Reverse Transcriptase, 1.1  $\mu$ l DTT and primers and probes at a  
200 final concentration of 900 nM and 250 nM respectively. Template was diluted 1:100 for  
201 measuring PMMoV and BCoV. Primer and probes were purchased from IDT (sequences in Table  
202 3). Droplets were generated using the AutoDG Automated Droplet Generator (Bio-Rad). PCR  
203 was performed using Mastercycler Pro with the following cycling conditions: reverse  
204 transcription at 50°C for 60 minutes, enzyme activation at 95°C for 5 minutes, 40 cycles of  
205 denaturation at 95°C for 30 seconds and annealing and extension at 61°C (for SARS-CoV-2  
206 targets) or 56°C (for PMMoV/BCoV targets) for 30 seconds, enzyme deactivation at 98°C for 10  
207 minutes then an indefinite hold at 4°C. The ramp rate for temperature changes were set to  
208 2°C/second and the final hold at 4°C was performed for a minimum of 30 minutes to allow the  
209 droplets to stabilize. Droplets were analyzed using the QX200 Droplet Reader (Bio-Rad). All  
210 liquid transfers were performed using the Agilent Bravo (Agilent Technologies).

211  
212 Thresholding was carried out using QuantaSoft™ Analysis Pro Software (Bio-Rad, version  
213 1.0.596). In order for a sample to be recorded as positive, it had to have at least 3 positive  
214 droplets.

215  
216 For the wastewater samples, concentrations of RNA targets were converted to concentrations  
217 per dry weight of solids in units of copies/g dry weight using dimensional analysis. The dry  
218 weight of the dewatered solids was determined by drying (23). Using this approach, three

219 positive droplets corresponds to a concentration between ~500-1000 cp/g; the range in values  
220 is a result of the range in the equivalent mass of dry solids added to the wells. The total error is  
221 reported as standard deviations and includes the errors associated with the Poisson distribution  
222 and the variability among the 10 replicate wells.

223

224 **Variants present in regional clinical specimens.** The 7-d, centered, rolling average fraction of  
225 clinical specimens sequenced from the State of California classified as Alpha, Beta, Gamma, Mu,  
226 Lambda, Delta, and Omicron as a function of specimen collection data were acquired through  
227 outbreak.info which collates data from GISAID. Data were downloaded from outbreak.info on  
228 January 5, 2022 for all variants, except for Omicron for which data were downloaded on  
229 January 10, 2022. Data were acquired in the form of time series plots, and data were extracted  
230 using PlotDigitizer (<https://plotdigitizer.com/>).

231

232 **Statistics.** We hypothesize that wastewater concentrations of characteristic variant mutations  
233 are associated positively with the proportion of infections caused by the variant in the  
234 contributing population. Because data on incidence rates of COVID-19 caused by specific  
235 variants at the sewershed level are not readily available, we used state-level data on the  
236 fraction of sequenced clinical specimens identified as specific variants to represent this  
237 variable. We normalized the wastewater concentration of the variant mutation by the  
238 concentration of the N gene to represent the fraction of total SARS-CoV-2 RNA (represented by  
239 the N gene assay target which is conserved across variants) that comes from the variant;  
240 hereafter this concentration is referred to as the relative concentration of the mutation. We

241 applied a five adjacent sample box-average smoothing algorithm to the relative concentrations  
242 to aid in visualization, but used raw data in statistical analyses. We used Kendall's tau (hereafter  
243 tau) to test for associations between the relative concentration and the fraction of clinical  
244 specimens assigned to the corresponding variant as the two variables were not normally  
245 distributed (Shapiro Wilk test,  $p < 0.05$  for all). The measured relative concentration was  
246 matched to the 7-d, centered, rolling average fraction of clinical specimens classified as the  
247 associated variant obtained from outbreak.info.

248

## 249 **Results**

250 **Lambda, Mu and Beta/Gamma Mutation Assay specificity.** In silico analysis of the Lambda,  
251 Mu Beta/Gamma, and Omicron mutation assays indicated no cross reactivity between the  
252 variant mutation assays and deposited sequences in NCBI. When challenged against the  
253 respiratory virus panel and gRNA from WT-SARS-CoV-2 and other variants (Table 1) no cross  
254 reactivity was observed. When mutation assays were tested on their target variant gRNA  
255 diluted in a background of high and low WT-SARS-CoV-2 RNA, there was no evidence of cross  
256 reactivity (Figure 1). Positive and negative controls run on all the ddPCR plates were positive  
257 and negative. These results suggest that the variant mutation ddRT-PCR assays are specific. Yu  
258 et al. (19) provide details on the specificity and sensitivity of the Alpha and Delta mutation  
259 assays, which are also specific and sensitive.

260

261 **Variant mutation RNA in wastewater.** All positive and negative controls were positive and  
262 negative respectively, indicating assays performed well and without contamination. BCoV

263 recoveries were higher than 10% and PMMoV concentrations were within the expected range  
264 for the POTW suggesting an efficient and acceptable recovery of RNA during RNA extraction  
265 (Figure S1).

266  
267 As described previously by Yu et al. (19), the Alpha mutation was not detected in wastewater  
268 solids prior to January 2021. After that time, it was detected in low relative concentrations until  
269 late March 2021, when its relative concentration started to increase until early June 2021 when  
270 its relative concentration peaked. The concentration began to decrease until the mutation  
271 became undetectable in late June 2021 (Figure 2).

272  
273 The delta mutation was not detected in wastewater solids until early April 2021 at which time it  
274 increased and was detectable for about a month before it fell to non-detectable levels again for  
275 two weeks. Thereafter, the concentration of the delta mutation rose over the month of June  
276 until it was present at about the same concentration as the N gene, thereafter the  
277 concentration stayed approximately equivalent to the N gene until the beginning of December  
278 2021 (Figure 2). The relative concentration subsequently decreased until the end of December  
279 2021.

280  
281 The omicron mutation was absent in the samples tested prior to 11 December 2021. After first  
282 detected on 11 December, the concentrations rose steadily until the relative concentration was  
283 close to 1 at the end of December (Figure 2).

284

285 The mutation present in Beta and Gamma was rarely detected in wastewater solids (Figure 2).  
286 It was not detected in wastewater until late May 2021 when it was detected at a very low  
287 relative concentration. It was detected a total of 3 times between late May 2021 and the end of  
288 July 2021, all at low concentrations relative to the N gene.

289  
290 The mutation present in Mu was not detected until May 2021 when it was detected at a fairly  
291 high concentration relative to the N gene in a single sample. Thereafter, it was not detected  
292 again until mid June after which its relative concentration increased for 1 month until the  
293 beginning of July and then decreased over the following month until the beginning of August  
294 after which the mutation was no longer detected (Figure 2). The lambda mutation assay was  
295 applied to 2 samples in November 2021 and was not detected.

296  
297 The 5-sample smoothed relative concentrations of the Alpha, Delta, Mu, and Omicron  
298 mutations, and the raw relative concentrations of the Beta/Gamma mutations are shown in  
299 Figure 3 along with the 7-d rolling average fraction of clinical specimens from the state assigned  
300 as each variant. The temporal trends in the relative wastewater concentrations and clinical  
301 specimen data are qualitatively similar. The wastewater variant mutation data (raw data, Figure  
302 2) are positively, significantly associated with the clinical variant data ( $\tau = 0.75$ ,  $p < 10^{-15}$  for  
303 Alpha,  $\tau = 0.42$ ,  $p < 10^{-13}$  for Delta,  $\tau = 0.91$ ,  $p < 10^{-13}$  for Omicron,  $\tau = 0.36$ ,  $p < 10^{-4}$  for Mu)  
304 with the exception of data for Beta/Gamma. The relative concentration of the Beta/Gamma  
305 mutation was positively associated with the fraction of clinical specimens assigned as Beta and  
306 Gamma ( $\tau = 0.14$ ,  $p = 0.5$ ), but the association was not statistically significant. This may be

307 due to the relatively low cadence of measurements as we only measured the mutation once  
308 per week; this is low compared to frequency of variability typically observed in wastewater  
309 measurements (1). There was no reported case of Lambda in the state from November 2021,  
310 and our lack of detection of the Lambda mutation in that month is consistent with this. The  
311 positive associations between relative variant mutation concentrations and the fraction of  
312 clinical specimens assigned to Alpha and Delta is consistent with findings described by Yu et al.  
313 (19) using sewershed-aggregated clinical data over a different time period.

314

## 315 **Discussion**

316 Wastewater results are indicative of the replacements of consecutive variants in circulation  
317 over time. The decline in relative wastewater concentrations of the Alpha mutation is  
318 coincident with the rise in relative wastewater concentrations of the Delta mutation suggestive  
319 of Delta outcompeting Alpha in causing infections in susceptible populations. Beta and Gamma  
320 mutations began to appear in wastewater along with Mu mutations as the relative  
321 concentration of the Delta mutation was rising. It appears these variants were also present but  
322 not able to compete with Delta as their relative concentrations decreased to non-detect shortly  
323 after their appearance in wastewater. The increase in relative wastewater concentrations of the  
324 Omicron mutation is coincident with the decline in the relative concentrations of the Delta  
325 mutation suggesting Omicron potentially outcompeting Delta, or a large increase in Omicron  
326 incident cases atop of a stable background of Delta incident cases.

327



328 Several other studies have reported agreement between detection of characteristic variant  
329 mutations in wastewater and the occurrence of variants in clinical specimens. Lee et al. (14)  
330 report a three fold higher increase in a characteristic mutation in Alpha in wastewater from  
331 January to March 2021, comparable to an increased fraction in Alpha sequences from clinical  
332 samples deposited in GISAID during the same time period. Graber et al. (15) report agreement  
333 in wastewater trends of a characteristic mutation from Alpha and data aggregated at the city  
334 level on Alpha circulation based on clinical specimens. Yaniv et al. (18) report lack of detection  
335 of a characteristic mutation in Alpha in wastewater when clinical data suggests it was not  
336 circulating.

337  
338 The clinical data used in this study are imperfect. The fraction of sequenced clinical specimens  
339 assigned to each variant may be biased by the selection of specimens to sequence, and the  
340 number of specimens sent for sequencing. The data displayed at Figure 3 are aggregated across  
341 the state, and may not reflect the occurrence of infections caused by different variants in the  
342 population contributing to the sewershed and represented in the wastewater data, particularly  
343 for variants with low occurrence rates. Despite these limitations, the wastewater variant  
344 mutation measurements correlate well with the variant clinical data.

345  
346 SARS-CoV-2 RNA in wastewater is a complex mixture of gRNA of all circulating variants in a  
347 given community. SARS-CoV-2 gRNA present in wastewater may be present in an intact or  
348 damaged viral capsid with or without an envelope (30), and may have undergone damage or  
349 fragmentation (11). In contrast, a clinical specimen contains numerous copies of one SARS-CoV-

350 2 variant, with the gRNA likely intact. Given the complexity of wastewater SARS-CoV-2 gRNA,  
351 the presence of a single characteristic mutation in wastewater cannot definitively indicate that  
352 a variant is present because a variant is defined by the presence of multiple mutations on a  
353 single genome. A single characteristic mutation detected in a wastewater sample could  
354 theoretically be from a different variant, known or unknown, containing the same mutation.  
355 Even the detection of two mutations characteristic of a specific variant in wastewater does not  
356 prove the variant is present, because those two mutations could have originated from different  
357 genomes. Moreover, the characteristic mutations used in this study are not present in 100% of  
358 the associated variant genomes. Despite these limitations, our results suggest that the  
359 concentration of a single mutation characteristic of a variant of concern over the concentration  
360 of a conserved SARS-CoV-2 target (the N gene) is associated with the proportion of regional  
361 infections caused by the variant.

362  
363 These findings suggest that for variants of concern, valuable insights are available on the  
364 circulation of the variants through the use of wastewater, and these insights are attainable  
365 using assays that target a single characteristic variant mutation. Development of assays for  
366 SARS-CoV-2 variants requires in silico assay design, procurement of primers, probes and  
367 positive control material, and specificity and sensitivity testing. The rate limiting step in this  
368 process, we have found, is the procurement process. Targeted ddRT-PCR assays can be applied  
369 to samples with a turnaround time for results of less than 24 hours, and new targeted assays  
370 can be quickly developed and applied to wastewater when new variants are identified and  
371 expected to spread into communities to gain insight into their local emergence. We were able

372 to implement this process in real-time for development and implementation of the Omicron  
373 mutation assay, which we were able to apply to daily samples at this POTW starting 6 Dec 2021  
374 to capture the emergence of the variant at high resolution.

375

376 **Acknowledgments.** This work was funded by a gift from the CDC Foundation. The funders had  
377 no role in study design, data collection and interpretation, or the decision to submit the work  
378 for publication. We acknowledge the following individuals for assistance with wastewater solids  
379 collection: Payal Sarkar, Noel Enoki, and Amy Wong.

380

381 References

382

383

- 384 1. Wolfe MK, Topol A, Knudson A, Simpson A, White B, Duc V, Yu A, Li L, Balliet M,  
385 Stoddard P, Han G, Wigginton KR, Boehm A. 2021. High-Frequency, High-Throughput  
386 Quantification of SARS-CoV-2 RNA in Wastewater Settled Solids at Eight Publicly Owned  
387 Treatment Works in Northern California Shows Strong Association with COVID-19  
388 Incidence. *mSystems* 0:e00829-21.
- 389 2. Whitney ON, Kennedy LC, Fan VB, Hinkle A, Kantor R, Greenwald H, Crits-Christoph A,  
390 Al-Shayeb B, Chaplin M, Maurer AC, Tjian R, Nelson KL. 2021. Sewage, Salt, Silica, and  
391 SARS-CoV-2 (4S): An Economical Kit-Free Method for Direct Capture of SARS-CoV-2  
392 RNA from Wastewater. *Environ Sci Technol* 55:4880–4888.
- 393 3. Peccia J, Zulli A, Brackney DE, Grubaugh ND, Kaplan EH, Casanovas-Massana A, Ko AI,  
394 Malik AA, Wang D, Wang M, Warren JL, Weinberger DM, Omer SB. 2020. SARS-CoV-2  
395 RNA concentrations in primary municipal sewage sludge as a leading indicator of COVID-  
396 19 outbreak dynamics. *Nature Biotechnology* 38:1164–1167.
- 397 4. Feng S, Roguet A, McClary-Gutierrez JS, Newton RJ, Kloczko N, Meiman JG, McLellan  
398 SL. 2021. Evaluation of sampling, analysis, and normalization methods for SARS-CoV-2  
399 concentrations in wastewater to assess COVID-19 burdens in Wisconsin communities.  
400 *ACS ES&T Water* 1:1955–1965.
- 401 5. Brouwer AF, Eisenberg JNS, Pomeroy CD, Shulman LM, Hindiyeh M, Manor Y, Grotto I,  
402 Koopman JS, Eisenberg MC. 2018. Epidemiology of the silent polio outbreak in Rahat,  
403 Israel, based on modeling of environmental surveillance data. *Proc Natl Acad Sci USA*  
404 115:E10625.
- 405 6. Bivins A, North D, Ahmad A, Ahmed W, Alm E, Been F, Bhattacharya P, Bijlsma L, Boehm  
406 AB, Brown J, Buttiglieri G, Calabro V, Carducci A, Castiglioni S, Cetecioglu Gurol Z,

- 407 Chakraborty S, Costa F, Curcio S, de los Reyes FL, Delgado Vela J, Farkas K, Fernandez-  
408 Casi X, Gerba C, Gerrity D, Girones R, Gonzalez R, Haramoto E, Harris A, Holden PA,  
409 Islam MdT, Jones DL, Kasprzyk-Hordern B, Kitajima M, Kotlarz N, Kumar M, Kuroda K, La  
410 Rosa G, Malpei F, Mautus M, McLellan SL, Medema G, Meschke JS, Mueller J, Newton  
411 RJ, Nilsson D, Noble RT, van Nuijs A, Peccia J, Perkins TA, Pickering AJ, Rose J,  
412 Sanchez G, Smith A, Stadler L, Stauber C, Thomas K, van der Voorn T, Wigginton K, Zhu  
413 K, Bibby K. 2020. Wastewater-Based Epidemiology: Global Collaborative to Maximize  
414 Contributions in the Fight Against COVID-19. *Environ Sci Technol* 54:7754–7757.
- 415 7. Hughes B, Duong D, White BJ, Wigginton KR, Chan EMG, Wolfe MK, Boehm AB. 2022.  
416 Respiratory Syncytial Virus (RSV) RNA in wastewater settled solids reflects RSV clinical  
417 positivity rates. *Environmental Science & Technology Letters* in press.
- 418 8. Centers for Disease Control and Prevention. 2021. SARS-CoV-2 Variant Classifications  
419 and Definitions.
- 420 9. World Health Organization. 2021. Tracking SARS-CoV-2 Variants.
- 421 10. Langenfeld K, Chin K, Roy A, Wigginton K, Duhaime MB. 2021. Comparison of  
422 ultrafiltration and iron chloride flocculation in the preparation of aquatic viromes from  
423 contrasting sample types. *PeerJ* 9:e111111.
- 424 11. Wurtzer S, Waldman P, Ferrier-Rembert A, Frenois-Veyrat G, Mouchel JM, Boni M, Maday  
425 Y, Marechal V, Moulin L. 2021. Several forms of SARS-CoV-2 RNA can be detected in  
426 wastewaters: Implication for wastewater-based epidemiology and risk assessment. *Water*  
427 *Research* 198:117183.
- 428 12. Crits-Christoph Alexander, Kantor Rose S., Olm Matthew R., Whitney Oscar N., Al-Shayeb  
429 Basem, Lou Yue Clare, Flamholz Avi, Kennedy Lauren C., Greenwald Hannah, Hinkle  
430 Adrian, Hetzel Jonathan, Spitzer Sara, Koble Jeffery, Tan Asako, Hyde Fred, Schroth  
431 Gary, Kuersten Scott, Banfield Jillian F., Nelson Kara L., Pettigrew Melinda M. Genome  
432 Sequencing of Sewage Detects Regionally Prevalent SARS-CoV-2 Variants. *mBio*


- 433 12:e02703-20.
- 434 13. Heijnen L, Elsinga G, de Graaf M, Molenkamp R, Koopmans MPG, Medema G. 2021.
- 435 Droplet digital RT-PCR to detect SARS-CoV-2 signature mutations of variants of concern
- 436 in wastewater. *Science of The Total Environment* 799:149456.
- 437 14. Lee WL, Imakaev M, Armas F, McElroy KA, Gu X, Duvallet C, Chandra F, Chen H, Leifels
- 438 M, Mendola S, Floyd-O'Sullivan R, Powell MM, Wilson ST, Berge KLJ, Lim CYJ, Wu F,
- 439 Xiao A, Moniz K, Ghaeli N, Matus M, Thompson J, Alm EJ. 2021. Quantitative SARS-CoV-
- 440 2 Alpha Variant B.1.1.7 Tracking in Wastewater by Allele-Specific RT-qPCR. *Environ Sci*
- 441 *Technol Lett* 8:675–682.
- 442 15. Graber TE, Mercier É, Bhatnagar K, Fuzzen M, D'Aoust PM, Hoang H-D, Tian X, Towhid
- 443 ST, Plaza-Diaz J, Eid W, Alain T, Butler A, Goodridge L, Servos M, Delatolla R. 2021. Near
- 444 real-time determination of B.1.1.7 in proportion to total SARS-CoV-2 viral load in
- 445 wastewater using an allele-specific primer extension PCR strategy. *Water Research*
- 446 205:117681.
- 447 16. Yaniv K, Ozer E, Kushmaro A. 2021. SARS-CoV-2 variants of concern, Gamma (P.1) and
- 448 Delta (B.1.617), sensitive detection and quantification in wastewater employing direct RT-
- 449 qPCR. medRxiv 2021.07.14.21260495.
- 450 17. Yaniv K, Ozer E, Shagan M, Lakkakula S, Plotkin N, Bhandarkar NS, Kushmaro A. 2021.
- 451 Direct RT-qPCR assay for SARS-CoV-2 variants of concern (Alpha, B.1.1.7 and Beta,
- 452 B.1.351) detection and quantification in wastewater. *Environmental Research* 201:111653.
- 453 18. Yaniv K, Ozer E, Lewis Y, Kushmaro A. 2021. RT-qPCR assays for SARS-CoV-2 variants
- 454 of concern in wastewater reveals compromised vaccination-induced immunity. *Water*
- 455 *Research* 207:117808.
- 456 19. Yu A, Hughes B, Wolfe M, Leon T, Duong D, Rabe A, Kennedy L, Ravuri S, White B,
- 457 Wigginton KR, Boehm A, Vugia D. 2021. Research Square [https://doi.org/10.21203/rs.3.rs-](https://doi.org/10.21203/rs.3.rs-1083575/v1)
- 458 1083575/v1.

- 459 20. Kim S, Kennedy LC, Wolfe MK, Criddle CS, Duong DH, Topol A, White BJ, Kantor RS,  
460 Nelson KL, Steele JA, Langlois K, Griffith JF, Zimmer-Faust AG, McLellan SL, Schussman  
461 MK, Ammerman M, Wigginton KR, Bakker KM, Boehm AB. 2021. SARS-CoV-2 RNA is  
462 enriched by orders of magnitude in solid relative to liquid wastewater at publicly owned  
463 treatment works. medRxiv 2021.11.10.21266138.
- 464 21. Graham KE, Loeb SK, Wolfe MK, Catoe D, Sinnott-Armstrong N, Kim S, Yamahara KM,  
465 Sassoubre LM, Mendoza Grijalva LM, Roldan-Hernandez L, Langenfeld K, Wigginton KR,  
466 Boehm AB. 2021. SARS-CoV-2 RNA in Wastewater Settled Solids Is Associated with  
467 COVID-19 Cases in a Large Urban Sewershed. *Environ Sci Technol* 55:488–498.
- 468 22. Topol A, Wolfe M, Wigginton K, White B, Boehm A. 2021. High Throughput RNA Extraction  
469 and PCR Inhibitor Removal of Settled Solids for Wastewater Surveillance of SARS-CoV-2  
470 RNA. protocols.io.
- 471 23. Topol A, Wolfe M, White B, Wigginton K, Boehm A. 2021. High Throughput pre-analytical  
472 processing of wastewater settled solids for SARS-CoV-2 RNA analyses. protocols.io.
- 473 24. Huisman JS, Scire J, Caduff L, Fernandez-Cassi X, Ganesanandamoorthy P, Kull A,  
474 Scheidegger A, Stachler E, Boehm AB, Hughes B, Knudson A, Topol A, Wigginton KR,  
475 Wolfe MK, Kohn T, Ort C, Stadler T, Julian TR. 2021. Wastewater-based estimation of the  
476 effective reproductive number of SARS-CoV-2. medRxiv 2021.04.29.21255961.
- 477 25. Topol A, Wolfe M, White B, Wigginton K, Boehm A. 2021. High Throughput SARS-COV-2,  
478 PMMOV, and BCoV quantification in settled solids using digital RT-PCR. protocols.io.
- 479 26. Kitajima M, Sassi HP, Torrey JR. 2018. Pepper mild mottle virus as a water quality  
480 indicator. *npj Clean Water* 1:19.
- 481 27. Symonds EM, Nguyen KH, Harwood VJ, Breitbart M. 2018. Pepper mild mottle virus: A  
482 plant pathogen with a greater purpose in (waste)water treatment development and public  
483 health management. *Water Research* 144:1–12.
- 484 28. McClary-Gutierrez JS, Aanderud ZT, Al-faliti M, Duvallet C, Gonzalez R, Guzman J, Holm

- 485 RH, Jahne MA, Kantor RS, Katsivelis P, Kuhn KG, Langan LM, Mansfeldt C, McLellan SL,  
486 Mendoza Grijalva LM, Murnane KS, Naughton CC, Packman AI, Paraskevopoulos S,  
487 Radniecki TS, Roman FA, Shrestha A, Stadler LB, Steele JA, Swalla BM, Vikesland P,  
488 Wartell B, Wilusz CJ, Wong JCC, Boehm AB, Halden RU, Bibby K, Delgado Vela J. 2021.  
489 Standardizing data reporting in the research community to enhance the utility of open data  
490 for SARS-CoV-2 wastewater surveillance. *Environ Sci: Water Res Technol* 7:1545–1551.
- 491 29. Borchardt MA, Boehm AB, Salit M, Spencer SK, Wigginton KR, Noble RT. 2021. The  
492 Environmental Microbiology Minimum Information (EMMI) Guidelines: qPCR and dPCR  
493 Quality and Reporting for Environmental Microbiology. *Environ Sci Technol* 55:10210–  
494 10223.
- 495 30. Robinson CA, Hsieh H-Y, Hsu S-Y, Wang Y, Salcedo BT, Belenchia A, Klutts J, Zemmer  
496 S, Reynolds M, Semkiw E, Foley T, Wan X, Wieberg CG, Wenzel J, Lin C-H, Johnson MC.  
497 2022. Defining biological and biophysical properties of SARS-CoV-2 genetic material in  
498 wastewater. *Science of The Total Environment* 807:150786.


499  
500  
501  
502






503  
504  
505  
506  
507  
508  
509  
510  
511

Figure 1. Copies (cp) of mutations measured when RNA containing the mutation was diluted into no, low, and high background of WT-gRNA. Low background is 100 copies/well and high background is 10,000 copies/well where “copies” refers to copies of genomes of WT-gRNA. Markers show average cross three replicate wells and error bars represent standard deviations. In some cases, the error bar is not visible because it is smaller than the marker.



512  
 513 Figure 2. Left column. Concentrations (copies (cp) per gram dry weight) of the N gene and the indicated  
 514 mutation in wastewater solids as a function of time. Open circles indicate non-detects for the mutation  
 515 gene. Error bars represent standard deviations and include poisson error and replicate well error and  
 516 was output from the ddPCR machine software as “total error”. Right column. The concentration of the  
 517 mutation normalized by the concentration of the N gene as a function of time (“relative mutation  
 518 concentration”, unitless). The black line represents the 5-point smoothed value for the dates. Open  
 519 circles are non-detects. Non-detects are shown as 0 on the plots. The Alpha mutation data are from Yu  
 520 et al. (19); Delta mutation data through 7/31/21 are from Yu et al. (19).

521



522

523 Figure 3. Top graph. Five-point smoothed relative concentrations of mutations in wastewater  
524 solids (unitless) with the exception of E484K/N501Y which is the raw data, non-detects were  
525 taken as 0. Bottom plot. The fraction of all sequenced clinical specimens in California that were  
526 classified as the indicated variant (7-d rolling average from outbreak.info).

527  
 528 Table 1. Variants included in this study (column 1), the characteristic mutations that ddRT-PCR  
 529 assays were developed for (column 2), the percent of variant genomes with the mutation(s) in  
 530 column 2 (column 3), the positive control used in the sensitivity testing experiments (column 4),  
 531 and the SARS-CoV-2 genomes that were used, along with the respiratory panel, in the  
 532 specificity testing conducted in vitro (column 4).  
 533

Variant Name(s)	Mutation(s) (gene location)	Percentage of variant genomes, observed globally, with mutation(s) in GISAID as of 10 Jan 2022 (total number of variant genomes with mutations / total number of variant genomes)	Positive control used in sensitivity testing	SARS-CoV-2 genomes tested against <i>in vitro</i> for specificity
Alpha	HV69-70 (del69-70) (S gene)	97% (1,106,137 /1,143,476)	Reported in Yu et al. (19)	Reported in Yu et al. (19)
Delta	del156-157/R158G (S gene)	92% (3,644,016 /3,953,372)	Reported in Yu et al. (19)	Reported in Yu et al. (19)
Beta & Gamma	E484K/N501Y (S gene)	Gamma: 94% (112925/119761) Beta: 85% (34576/40553)	Positive clinical swab sequenced as P.1 (Gamma)	WT gRNA and Alpha
Mu	del256-257 (ORF3a)	95% (13,978 /14,712)	Positive clinical swab from Stanford sequenced as B.1.621	WT gRNA, Alpha, Beta, Delta and Gamma
Lambda	del247-253 (S gene)	84% (8029/9577)	gRNA from cultivated Lambda variant from Pinsky Lab C.37	WT gRNA, Alpha, Beta, Gamma, Delta, Mu
Omicron	del143-145 (S gene)	95% (212,997/224,673)	Synthetic Omicron gRNA from Twist control 48	WT gRNA, Alpha, Beta, Gamma, Delta, Mu, Lambda

534  
 535

536

Target	Primer/Probe	Sequence
N Gene	Forward	CATTACGTTTGGTGGACCCT
	Reverse	CCTTGCCATGTTGAGTGAGA
	Probe	CGCGATCAAAACAACGTCGG (5' FAM/ZEN/3' IBFQ)
BCoV	Forward	CTGGAAGTTGGTGGAGTT
	Reverse	ATTATCGGCCTAACATACATC
	Probe	CCTTCATATCTATACACATCAAGTTGTT (5' FAM/ZEN/3' IBFQ)
PMMoV	Forward	GAGTGGTTTGACCTTAACGTTTGA
	Reverse	TTGTCGGTTGCAATGCAAGT
	Probe	CCTACCGAAGCAAATG (5' HEX/ZEN/3' IBFQ)
HV69-70 (Alpha)	Forward	ACTCAGGACTTGTTCTTACCT
	Reverse	TGGTAGGACAGGGTTATCAAAC
	Probe	ATGCTATCTCTGGGACCAAT (5' FAM or HEX/ZEN/3' IBFQ)
E484K/N501Y (Beta and Gamma)	Forward	CTGAAATCTATCAGGCCGGT
	Reverse	GTTGGTAACCAACACCATAAG
	Probe	CACACCTTGAATGGTGTTAAAGGTT (5' FAM or HEX/ZEN/3' IBFQ)
del156-157/R158G (Delta)	Forward	ATTCGAAGACCCAGTCCCTA
	Reverse	AGGTCCATAAGAAAAGGCTGA
	Probe	TGGATGGAAAGTGGAGTTTATTCTAG (5' FAM or HEX/ZEN/3' IBFQ)
del256/257 (Mu)	Forward	CAAATTCACACAATCGACGGT
	Reverse	GTCGTCGTCGGTTCATCATA
	Probe	TCATCCGGAGTTATCCAGTAATGG(5' FAM or HEX/ZEN/3' IBFQ)
del247-253 (Lambda)	Forward	TCGGCTTTAGAACCATTGGT
	Reverse	TCAAGTGCACAGTCTACAGC
	Probe	TGCTTTACATAATTCTTCTTCAGTTGGAC(5' FAM or HEX/ZEN/3' IBFQ)
del143-145 (Omicron)	Forward	ATTCGAAGACCCAGTCCCTA
	Reverse	ACTCTGAACTCACTTTCCATCC
	Probe	TTGTAATGATCCATTTTTGGACCACAA(5' FAM or HEX/ZEN/3' IBFQ)

537 Table 2. Primer and probe sequences used in this study to target characteristic mutations in  
 538 variants. The variant containing the characteristic mutation is shown below the name of the  
 539 targeted mutation.  
 540

541  
542  
543

Variant mutation	Frequency of sampling	N	Previously published?	Time RNA stored at -80°C for samples newly processed as part of this study (days)
Mu	Biweekly: 1/21/21-3/30/21 Weekly: 4/1/21 - 5/25/21 3 per week: 5/26/21-11/15/21	90	No	4-300
Beta/Gamma	One sample from 2/23/21 Weekly: 4/17/21 - 7/26/21	16	No	0-2
Delta	Biweekly to weekly 2/7/21 - 5/1/21 3 per week: 5/1/21 - 9/3/21 Daily 9/4/21 - 11/30/21 3 per week 12/3/21 - 1/3/22	156	Partially, N=48 collected between 2/7/21 and 7/30/21 (19)	0-30
Alpha	Monthly: 7/14/20 - 3/25/21 Daily: 3/28/21 - 8/8/21	133	Yes (19)	NA
Lamda	Weekly for 2 weeks: 11/1/21 & 11/8/21	2	No	0-2
Omicron	Weekly: 11/2/21 - 11/23/21 3 per week: 11/29/21-12/5/21 Daily: 12/6/21 and 1/2/22	35	No	0 -30

544 Table 3. Frequency of sample collection for different assay applications, number of samples  
545 included in this study, whether any of the data have been published, and the time range that  
546 RNA samples were stored between extraction of RNA and running the PCR assays. RNA  
547 extraction occurred on the day of sample collection, as explained in the methods.  
548  
549